

Manmohan Singh *Editor*

# Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

 Springer

# Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines



Manmohan Singh

Editor

# Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

 Springer

*Editor*

Manmohan Singh, PhD  
Novartis Vaccines Research  
Cambridge, MA, USA

ISBN 978-1-4614-5379-6                      ISBN 978-1-4614-5380-2 (eBook)  
DOI 10.1007/978-1-4614-5380-2  
Springer New York Heidelberg Dordrecht London

Library of Congress Control Number: 2012952017

© Springer Science+Business Media New York 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

# Preface

Recent advances in our understanding of innate immunity have fueled the field of drug discovery with emphasis on developing better immune potentiators that can boost the host innate immune system. Targeting the host innate compartment has the unique advantage of triggering a rapid mobilization of key effector mechanisms to engender a strong immune response to a vaccine antigen. Several new class of molecules that target the innate immune system have been recently tested as potential vaccine adjuvants. These novel adjuvants also require rationally designed vaccine formulations and delivery systems that can provide maximum potency with acceptable safety in a prophylactic setting. These delivery systems contribute greatly on modifying and controlling the level of systemic exposure, avoiding the potential production of proinflammatory cytokines, improving safety and/or tolerability of the novel adjuvant.

One of the fascinating aspects of vaccine delivery for several decades now has been fully exploring the benefits and limitations of mucosal delivery. Exciting new adverts have been made in this regard using gene-based and attenuated oral vaccines. Immunization through the skin as the route of delivery of antigens holds great promise in making vaccines more patient compliant and needle free. Since most vaccines are complex compositions, new medium and high throughput tools have now emerged that help screen rapidly for excipients and stabilizers prior to running expensive preclinical animal studies. Several biophysical tools and assays are now being adapted to better characterize vaccine formulations.

In this book we have made an effort to cover new vaccine delivery technologies and discuss some of the next generation immune potentiators that could potentially be part of licensed products in the future. Detailed description of all leading vaccine technologies with their limitations should be of great help to researchers and students to enhance their understanding of these novel concepts. The book also has chapters on clinical and non-clinical safety evaluation of vaccine formulations which should be of great value in moving vaccines from research to clinic.

*Manmohan Singh*



# Contents

## Section I Novel Immune Potentiators and Delivery Systems for Enhancing Vaccine Potency

- 1 TLR7/8 Agonists as Vaccine Adjuvants** ..... 3  
Mark A. Tomai and John P. Vasilakos
- 2 Preclinical and Clinical Development of Synthetic iNKT-Cell  
Glycolipid Agonists as Vaccine Adjuvants**..... 19  
Josianne Nitcheu, Sandrine Crabe, Gwyn Davies, and Vincent Serra
- 3 Mucosal Vaccination: Opportunities and Challenges**..... 65  
Olga Borges and Gerrit Borchard
- 4 Oral Vaccination: Attenuated and Gene-Based** ..... 81  
Wendy Peters, Ciaran D. Scallan, and Sean N. Tucker

## Section II Design and Development of Next Generation Vaccines

- 5 Development of Biophysical Assays to Better Understand  
Adjuvanted Vaccine Formulation Potency and Stability** ..... 107  
James Chesko, Thomas Vedvick, and Steve Reed
- 6 High Throughput Screening for Stabilizers of Vaccine Antigens**..... 119  
C. Russell Middaugh, David B. Volkin, and Sangeeta B. Joshi
- 7 Exploring Novel Analytical Tools to Improve Characterization  
of Vaccine Formulations** ..... 145  
Michele Pallaoro
- 8 Immunobioengineering Approaches Towards Combinatorial  
Delivery of Immune-Modulators and Antigens**..... 161  
Ankur Singh, Pallab Pradhan, and Krishnendu Roy



### Section III Novel Delivery Technologies for Vaccines

- 9 Current Status of Electroporation Technologies for Vaccine Delivery** ..... 185  
 Claire F. Evans and Drew Hannaman
- 10 Microneedles for Intradermal Vaccination: Immunopotential and Formulation Aspects**..... 217  
 Alexander K. Andrianov
- 11 MicroCor<sup>®</sup> Transdermal Delivery System: A Safe, Efficient, and Convenient Transdermal System for Vaccine Administration** ..... 233  
 Parminder Singh, Guohua Chen, and Wade Worsham
- 12 Mimopath<sup>™</sup>-Based Vaccine Delivery** ..... 245  
 Kees Leenhouts

### Section IV Novel Particulate Delivery Systems for Vaccines and Adjuvants

- 13 NanoBio<sup>™</sup> Nanoemulsion for Mucosal Vaccine Delivery** ..... 269  
 Tarek Hamouda, Jakub Simon, Ali Fattom, and James Baker
- 14 Influenza Virosomes as Antigen Delivery System** ..... 287  
 Christian Moser and Mario Amacker
- 15 Matrix M Adjuvant Technology** ..... 309  
 Karin Lövgren Bengtsson

### Section V Safety Assessment of Next Generation Vaccines

- 16 Strategies for the Nonclinical Safety Assessment of Vaccines**..... 323  
 Jayanthi J. Wolf, Lisa M. Plitnick, and Danuta J. Herzyk
- 17 Safety Challenges Facing Next Generation Vaccines and the Role for Biomarkers**..... 351  
 S. Sohail Ahmed, Ernesto Oviedo-Orta, and Jeffrey Ulmer
- Index**..... 365

# Contributors

**S. Sohail Ahmed** Vaccines Research, Novartis Vaccines & Diagnostics, Siena, Italy

**Mario Amacker** Pevion Biotech AG, Ittigen, Switzerland

**Alexander K. Andrianov** Apogee Technology Inc., Norwood, MA, USA

**James Baker** NanoBio Corporation, Ann Arbor, MI, USA

**Gerrit Borchard** Center for Neuroscience and Cell Biology & Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

**Olga Borges** Center for Neuroscience and Cell Biology & Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

**Guohua Chen** Corium International, Inc., Menlo Park, CA, USA

**James Chesko** Infectious Disease Research Institute, Seattle, WA, USA

**Sandrine Crabe** WittyCell SAS, Evry, France

**Gwyn Davies** St George's University of London, Cranmer Terrace, London, UK

**Drew Hannaman** Ichor Medical Systems, San Diego, CA, USA

**Claire F. Evans** Ichor Medical Systems, San Diego, CA, USA

**Ali Fattom** NanoBio Corporation, Ann Arbor, MI, USA

**Tarek Hamouda** NanoBio Corporation, Ann Arbor, MI, USA

**Danuta J. Herzyk** Merck Research Laboratories, West Point, PA, USA

**Sangeeta B. Joshi** Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, KU School of Pharmacy, Kansas University, Lawrence, KS, USA

**Kees Leenhouts** Meditech Center, Mucosis B.V., Groningen, The Netherlands

**Karin Lövgren Bengtsson** CSO, Isconova AB, Uppsala, Sweden

**C. Russell Middaugh** Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, KU School of Pharmacy, Kansas University, Lawrence, KS, USA

**Christian Moser** Pevion Biotech AG, Ittigen, Switzerland

**Josianne Nitcheu** Wittycell SAS, Evry, France

**Ernesto Oviedo-Orta** Vaccines Research, Novartis Vaccines & Diagnostics, Siena, Italy

**Michele Pallaoro** Novartis Vaccines & Diagnostics, Siena, Italy

**Wendy Peters** Vaxart, Inc., San Francisco, CA, USA

**Lisa M. Plitnick** Merck Research Laboratories, West Point, PA, USA

**Pallab Pradhan** Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA

**Steve Reed** Infectious Disease Research Institute, Seattle, WA, USA

**Krishnendu Roy** Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA

**Ciaran D. Scallan** Vaxart, Inc., San Francisco, CA, USA

**Vincent Serra** Wittycell SAS, Evry, France

**Jakub Simon** NanoBio Corporation, Ann Arbor, MI, USA

**Ankur Singh** Woodruff School of Mechanical Engineering, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta GA, USA

**Parminder Singh** Corium International, Inc., Menlo Park, CA, USA

**Mark A. Tomai** 3M Drug Delivery Systems Division, 3M Center, St. Paul, MN, USA

**Sean N. Tucker** Vaxart, Inc., San Francisco, CA, USA

**Jeffrey Ulmer** Vaccines Research, Novartis Vaccines & Diagnostics, Siena, Italy

**John P. Vasilakos** 3M Drug Delivery Systems Division, 3M Center, St. Paul, MN, USA

**Thomas Vedvick** Infectious Disease Research Institute, Seattle, WA, USA

**David B. Volkin** Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, KU School of Pharmacy, Kansas University, Lawrence, KS, USA

**Jayanthi J. Wolf** Merck Research Laboratories, West Point, PA, USA

**Wade Worsham** Corium International, Inc., Menlo Park, CA, USA

**Section I**  
**Novel Immune Potentiators and Delivery**  
**Systems for Enhancing Vaccine Potency**

# Chapter 1

## TLR7/8 Agonists as Vaccine Adjuvants

Mark A. Tomai and John P. Vasilakos

### 1.1 Introduction

Small molecule TLR7/8 agonists have demonstrated great potential as vaccine adjuvants, since they quantitatively and qualitatively enhance both humoral and cellular immune responses. However, most small molecule TLR agonists evaluated thus far as vaccine adjuvants are highly soluble and have a propensity to rapidly disperse away from the vaccination site, resulting in decreased efficacy and increased systemic adverse effects. Intense effort and progress has been made to increase their ability to maintain close proximity to antigen at the administration site. Here, we will discuss three vaccine approaches utilizing small molecule TLR7/8 agonists as vaccine adjuvants. These approaches are designed to improve the adjuvanticity and to reduce the potential for systemic adverse events associated with these small molecule TLR7/8 agonists when used as vaccine adjuvants. One approach utilizes the TLR7/8 agonist resiquimod gel as a topically applied adjuvant at the vaccination site. The other two approaches utilize novel TLR7/8 agonists in a conventional vaccine format where the adjuvant and antigen are administered together. These novel TLR7/8 agonists are lipid modified or chemically modified for conjugation to antigen—all three approaches are designed to promote retention of the TLR7/8 agonists at the administration site in order to maintain their spatial and temporal proximity to the antigen, resulting in enhanced immune responses and reduced systemic adverse effects.

---

M.A. Tomai (✉)  
3M Drug Delivery Systems Division, 3M Center,  
Building 275-03-E-10, St. Paul, MN 55144, USA  
e-mail: matomai@mmm.com

J.P. Vasilakos  
3M Drug Delivery Systems Division, 3M Center,  
Building 260-04-S-13, St. Paul, MN 55125, USA  
e-mail: Jpvasilakos@mmm.com


## 1.2 The Need for New Vaccine Adjuvants

Despite the development of numerous successful vaccines, vaccines do not exist for many pathogens or cancers. Currently, inactivated pathogens, recombinant proteins, purified peptides, and DNA vaccines are being explored in order to address adverse events associated with live vaccines, and in some cases, to address the fact that live infectious agents do not confer protection. The major problem with most protein, peptide, and DNA vaccines is that they are poorly immunogenic or elicit an inappropriate immune response, and don't provide protection against the infectious agent or cancers. The question isn't whether an adjuvant is required, but what type of adjuvant or adjuvant combination will work best with a specific antigen or antigens for a specific disease indication. In addition, each antigen and adjuvant combination must be formulated to provide adequate stability and to ensure that the vaccine maximally stimulates the appropriate immune response in an acceptably safe and tolerable manner. Hence, the three key components of a vaccine are the antigen, adjuvant, and formulation. This chapter will focus on adjuvants, specifically small molecule TLR7/8 agonists.

Currently, there are very few vaccine adjuvants approved for human use. Aluminum salts (i.e., ALUM) are one of few US Food and Drug Administration approved adjuvants and is the most widely used adjuvant [1]. Additionally, MF59, an oil-in-water squalene emulsion, has been approved in some countries [2]. More recently, AS03 adjuvant (DL- $\alpha$ -tocopherol, squalene, polysorbate 80) and AS04 adjuvant (ALUM and monophosphoryl lipid A) have also been approved in some countries [3, 4]. These adjuvants are safe, but they do not uniformly or sufficiently enhance cell-mediated immune responses that are required for elimination of many intracellular organisms and cancers. Hence, adjuvants that drive cellular immunity, both CD4 and CD8 responses, are being investigated.

## 1.3 Toll-Like Receptors and Toll-Like Receptor Agonists

In order to understand how vaccines induce adaptive immune responses, we first must begin with how the innate immune system recognizes microorganisms. Several recognition strategies have been developed by the innate immune system to deal with the problem of detecting a broad range of heterogeneous and rapidly evolving pathogens. Specifically, the innate immune system possesses receptors, broadly classified as pattern recognition receptors (PRR), which specifically recognize conserved microbial molecular patterns [5, 6]. PRRs are predominantly expressed on or in phagocytic cells, such as dendritic cells, macrophages, neutrophils, monocytes, and to a lesser extent on other cell types. PRRs are germ-line encoded receptors, and unlike T-cell or B-cell receptors, don't undergo somatic mutation and clonal distribution. As such, PRRs are "hard-wired" to recognize conserved microbial molecular patterns known as pathogen-associated molecular patterns (PAMPs). PAMPs are classically characterized as a limited set of conserved molecular patterns unique to the microbial world and invariant among entire classes of pathogens [7]. Engagement of PRRs with PAMPs results in antimicrobial and inflammatory responses, including the production of



**Fig. 1.1** Conventional DC express TLR3, 4, 5, and 8, and when ligated with specific agonists, produce IL-12. Plasmacytoid DC express TLR7 and TLR9, and when ligated with their specific agonists, produce IFN- $\alpha$ . Adapted from Coffman et al. [3]

cytokines and chemokines that affect innate and adaptive immune responses. Indeed, it has become clear that innate immune cells and their PRRs are usually critical for the induction, magnitude, and quality of adaptive immune responses.

Toll-like receptors (TLRs) are one type of PRRs utilized by the innate immune system to recognize microbial pathogens. There are ten human TLRs; they are transmembrane-signaling proteins expressed on surface of the plasma membrane or endosomes. TLR1, 2, 4, 5, 6, and 10 are cell surface expressed, and TLR3, 7, 8, and 9 are expressed in endosome/lysosome membranes. Although innate immune cells express TLRs, all innate immune cells do not express the same TLRs. As an example, the majority of human dendritic cells (DC) can be classified as conventional DC (cDC) or plasmacytoid DC (pDC). Conventional DC express TLR3, 4, 5, and pDC express TLR7 and 9. Ligation of cDC TLRs results in the production of numerous cytokines including IL-12. In contrast, ligation of pDC TLRs results in the production of interferon alpha. Therefore cell-specific TLR expression results in differences in cytokine responses induced by various TLR agonists (Fig. 1.1).

Although the schematic in Fig. 1.1 is an oversimplification of the complexities of TLR expression patterns and cytokine responses resulting from TLR ligand